Five immunology assets in-licensed from BMS with potential to address unmet needs for patients with autoimmune diseases, including late-stage asset for lupus Bain Capital leads $300 million financing ...
After delaying a late-stage readout last year due to “irregularities” at certain study sites, pivotal data for Bristol Myers ...
Pharmaceutical Technology on MSN
BMS brings the buzz around late-stage readouts amid a so-so Q1
BMS is looking to Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy to drive ...
Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos ...
After several years of turning out solid growth, Bristol Myers Squibb knows it’s nearing a patent cliff that’ll wreak havoc later this decade. Still, the company believes a “diversified” ...
Bristol Myers Squibb has called time on a bispecific antibody partnership with Zymeworks that the Big Pharma inherited from ...
Bristol Myers Squibb's valuation metrics show the stock is a bona fide bargain. However, valuation metrics can be misleading ...
Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinical development. The deal – ...
As the global energy landscape undergoes a rapid transition toward electrification and sustainable storage, the 2026 World Battery & Energy Storage Industry Expo (WBE) serves as a pivotal stage for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results